

**Efecto de la suplementación con
ácidos grasos omega -3 sobre la
toxicidad secundaria a
quimioterapia neoadyuvante en
pacientes con cáncer de mama
localmente avanzado: ensayo
suplementación on neoadjuvant
clínico aleatorizado**
**chemotherapy-induced toxicity in
patients with locally advanced
breast cancer: a randomized,
controlled, double-blinded
clinical trial**

OR 2338

Effects of omega-3 fatty acids supplementation on neoadjuvant chemotherapy-induced toxicity in patients with locally advanced breast cancer: a randomized, controlled, double-blinded clinical trial

Efecto de la suplementación con ácidos grasos omega -3 sobre la toxicidad secundaria a tratamiento neoadyuvante en pacientes con cáncer de mama localmente avanzado: Ensayo clínico aleatorizado

Fabiola De la Rosa Oliva^{1,2,3}, Abelardo Meneses García¹, Héctor Ruiz Calzada^{3,4}, Horacio Astudillo de la Vega⁵, Enrique Bargalló Rocha E⁶, Fernando Lara-Medina⁶, Alberto Alvarado-Miranda⁶, Juan Matus-Santos⁶, Diana Flores-Díaz⁵, Luis F. Oñate-Acuña⁵, Gabriela Gutiérrez- Salmeán², Erika Ruiz-García E¹ and Antonio Ibarra²

¹Laboratorio de Medicina Traslacional. Instituto Nacional de Cancerología. Ciudad de México, México. ²Centro de Investigación en Ciencias de la Salud (CICSA). Facultad de Ciencias de la Salud. Universidad Anáhuac México Campus Norte. Huixquilucan, México. ³Universidad Autónoma de Zacatecas. Zacatecas, México. ⁴Hospital General No. 26 ISSSTE Zacatecas. Zacatecas, México. ⁵Laboratorio de Investigación Traslacional y Terapia Celular. Hospital de Oncología CMN SXXI-IMSS. Ciudad de México, México. ⁶Departamento de Tumores Mamarios. Instituto Nacional de Cancerología. Ciudad de México, México

Received: 02/10/2018

Accepted: 11/03/2019

Correspondence: Antonio Ibarra and Gabriela Gutiérrez Salmean. Centro de Investigación en Ciencias de la Salud (CICSA). Facultad de Ciencias de la Salud. Universidad Anáhuac México. Campus Norte. Av. Universidad Anáhuac, 46. Lomas Anáhuac. 52786 Huixquilucan, Estado de México

e-mail: jose.ibarra@anahuac.mx; gabriela.gutierrez@anahuac.mx

ABSTRACT

Background: antineoplastic treatment for locally advanced breast cancer (LABC) includes neoadjuvant chemotherapy (NeoCT). However, side effects occur frequently, affecting the functional capacity and quality of life of patients as a result of the proinflammatory state of this therapy. In this work, omega-3 polyunsaturated fatty acids (PUFA Ω -3) were administered as they have been reported to modulate some molecular pathways such as nuclear factor-kappa B (NF- κ B), which is associated with toxicity secondary to the administration of anthracyclines.

Objective: to evaluate the effects of PUFA Ω -3 on the toxicity, side effects, body composition, cardiometabolic profile and quality of life in women with LABC after NeoCT.

Methods: fifty-three women with LABC were included in a double-blinded, placebo-controlled clinical trial. Patients randomly received 2.4 g/day of PUFA Ω -3 (EPA 1.6 g and DHA 0.8 g) or placebo during NeoCT with adriamycin/cyclophosphamide followed by paclitaxel+/-trastuzumab. Adverse effects related to chemotherapy were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE, version 4.03) and the Subjective Global Scale of the Edmonton Symptom Assessment System (ESAS). Body composition and cardiometabolic blood profile were also evaluated.

Results: no significant differences were found between groups in the hematological and anthropometric toxicity parameters. Within the

Edmonton scale, xerostomia presented a significant improvement ($p = 0.032$) in patients supplemented with PUFA Ω -3.

Conclusion: supplementation with PUFA Ω -3 showed no change in body composition, cardiometabolic profile or toxicity due to NeoCT. Only showed significant improvement in xerostomia.

Key words: PUFA Ω -3. Neoadjuvant chemotherapy. Breast cancer. Toxicity. Body composition.

RESUMEN

Introducción: uno de los tratamientos para el cáncer de mama localmente avanzado (CMLA), es la quimioterapia neoadyuvante (QTNeo). Sin embargo, los efectos secundarios afectan el estado funcional y la calidad de vida de los pacientes, especialmente por el estado inflamatorio que originan. En este trabajo se administraron los ácidos grasos poliinsaturados omega 3 (AGPI Ω -3), ya que modulan negativamente algunas vías moleculares como las que inducen la activación del factor nuclear-kappa B (NF- κ B), involucrado con los mecanismos de toxicidad secundaria a la administración de antraciclinas.

Objetivo: valorar el efecto de los AGPI n-3, sobre la toxicidad de la QTNeo, la composición corporal, el perfil cardiometabólico y la calidad de vida en mujeres con CMLA durante la QTNeo.

Métodos: se incluyeron cincuenta y tres mujeres con CMLA, en un estudio clínico doble ciego controlado con placebo. Las pacientes recibieron aleatoriamente 2,4 g/día de AGPI Ω -3 (EPA 1,6 g y DHA 0,8 g) o placebo durante la quimioterapia neoadyuvante con adriamicina/ciclofosfamida seguido de paclitaxel +/- trastuzumab. Se evaluaron los eventos adversos relacionados con la quimioterapia mediante los Criterios de terminología común para eventos adversos

(CTCAE, versión 4.03) y la escala Global subjetiva del Sistema de Evaluación de los Síntomas de Edmonton (ESAS), la composición corporal y la toxicidad cardiometabólica.

Resultados: no hubo diferencias significativas entre los grupos en los parámetros de toxicidad hematológica y antropométricos. La xerostomía de la escala de Edmonton, presento una mejora significativa ($p = 0,032$) en los pacientes suplementados con AGPI Ω -3.

Conclusión: la suplementación con AGPI Ω -3 no mostró cambios en la composición corporal ni en la toxicidad del tratamiento neoadyuvante, solamente se encontró una mejoría significativa en la xerostomía.

Palabras clave: Ácidos grasos poliinsaturados omega 3 (AGPI Ω -3). Quimioterapia neoadyuvante. Cáncer de mama. Toxicidad. Composición corporal.

INTRODUCTION

Breast cancer is a public health problem worldwide (1) due to its high incidence as well as the toxicity of antineoplastic treatments that affect nutritional status as well as the quality of life (2). Moreover, patients with cancer frequently present alterations in body composition, such as loss of muscle mass and increased adipose tissue, which, in turn, relate to an increased risk of developing cardiometabolic alterations (8,9). These conditions are also considered to be secondary to the chronic inflammation (10,11). Likewise, some studies consider that the affection of body composition and the increase of systemic inflammatory mediators cause an increase in toxicity secondary to chemotherapy, thus yielding a vicious circle that negatively affects the quality of life of patients presenting an increase in symptomatology associated with chemotherapy as fatigue, pain, anxiety and depression, as well as sleep disturbances and an increased risk of early recurrence of the disease (3,6,12). Hence, co-adjuvant therapies are of profound interest.

In line with this, some studies have shown that omega 3 polyunsaturated fatty acids (PUFA Ω -3) may attenuate such side effects and, in addition, help to maintain body weight and preserve muscle mass (3-6). These benefits have been attributed to their anti-inflammatory effects, including an increase in circulating adiponectin and other anti-inflammatory molecules, concomitant to the suppression of proinflammatory pathways such as that mediated by nuclear factor-kappa B (NF- κ B) (3,6,7). Previous studies in breast and esophageal cancer have reported that supplementation with PUFA Ω -3 during chemotherapy improves the quality of life of these patients by improving anemia, thrombocytopenia and reducing gastrointestinal toxicity (mucositis, stomatitis and diarrhea) (13,14). In addition, supplementation with 2.5 g PUFA Ω -3 during chemotherapy in patients with lung cancer showed to preserve body weight and skeletal muscle (15).

In breast cancer, neoadjuvant chemotherapy (NeoCT) is the first-line treatment in patients with locally advanced disease (16). NeoCT is administered before a radical treatment (surgical and/or radiotherapy) in order to control the systemic disease, reduce the size of the tumor and, in some cases, achieve a complete pathological response of the tumor. This improves locoregional control, disease-free periods and the overall survival of patients (17). However, nowadays there are no studies analyzing the toxic effect of NeoCT in patients with locally advanced breast cancer (LABC).

Based on these observations, we hypothesized that the supplementation with PUFA Ω -3 may decrease the toxicity secondary to chemotherapy during the NeoCT treatment in patients with LABC.

MATERIALS Y METHODS

Study design

A randomized, double-blinded, placebo-controlled trial was conducted during the six months of NeoCT of 53 women with LABC. They were randomized into two groups: 27 women for the PUFA Ω -3 group and 26 for the placebo group. Inclusion criteria were: women aged 18-80 years, with a diagnosis of LABC confirmed by histopathology, in a clinical stage IIA-III B. Exclusion criteria were: patients who received chemotherapy different from anthracyclines-taxanes, uncontrolled chronic diseases (chronic heart failure, renal insufficiency, hypertension, diabetes mellitus), known allergy to fish or fish oil, alterations of the digestive tract that would prevent the intake of the supplement, consumption of other supplements with PUFA Ω -3, and BMI < 18 kg/m².

This study was conducted in accordance with the guidelines of the Declaration of Helsinki. It was approved by the Universidad Anáhuac México IRB and the Ethics Committee of the National Commission of Scientific Research of the National Institute of Cancerology (reg. 015/035/IMO CEI/971). Each participant provided written informed consent.

Treatment

All participants received NeoCT: four cycles of adriamycin and cyclophosphamide, followed by 12 weeks of paclitaxel +/- trastuzumab. Patients also received an oral supplement with PUFA Ω -3 derived from fish oil in gel capsules, daily dosed at 2.4 g (four capsules) in a 2:1 ratio of DHA/EPA, or a placebo (sunflower oil) during the six months of chemotherapy. Capsules were identical in appearance (Alta Tecnología en Alimentos Funcionales S.A. de C.V., Mexico) and in accordance with the Good Manufacturing Practices for food. Adherence was assessed every month by counting the leftover capsules of the previous month; patients with compliance < 90% were excluded from analysis.

Toxicity evaluation

Adverse events were evaluated by the attending physician, three weeks after the beginning of NeoCT, in accordance with the CTCAE (version 4.03, June 2010). Acute events, unscheduled hospital admissions and delayed chemotherapy were obtained from medical records. The patient's perspective of some symptoms (including pain, fatigue, drowsiness, nausea, appetite, dyspnea, anxiety, insomnia, malaise, and xerostomia) was evaluated with the Edmonton Symptom Assessment System (ESAS, Spanish version) (18,19).

Body composition evaluation

Weight and body composition (body fat mass, fat-free mass, skeletal muscle, body mass index [BMI]) were evaluated by bioelectrical impedance (Inbody 720; Biospace, Ltd., Seoul Korea), using an eight-point tetrapolar tactile electrode system. Measurements were obtained at the beginning of the study, and again at three and six months (20).

Metabolic evaluation

Blood samples were obtained at the beginning of the study (without treatment), three and six months after therapy. Serum glucose, lipid profile (total cholesterol, HDL and LDL cholesterol and triglycerides), insulin, glycated hemoglobin (HbA1c), liver function tests, urea and creatinine were determined by immunoassay (Beckman Coulter, California, USA). Insulin resistance (IR) was estimated using the homeostatic model (HOMA-IR) (21).

Statistical analysis

The Kolmogorov-Smirnov test was used to evaluate normality of the data. Demographic variables are presented as descriptive statistics. The differences between PUFA Ω -3 and the placebo groups were compared using Student's t test for independent groups. Repeated measures ANOVA was used to evaluate intra-group changes. Proportions were

evaluated using the Fisher's exact test. Statistical significance was considered when $p < 0.05$.

RESULTS

A total of 81 patients were screened for this study; 53 were included and randomized: 27 women for PUFA Ω -3 and 26 for placebo supplementation (Fig. 1). Recruitment was carried out from March 2015 to January 2016, whereas clinical follow-up was completed in September 2017.

Mean age of the patients was 50.7 ± 2.1 (range 28-72) and 49.5 ± 2.1 years (range 29-68) in the groups of PUFA Ω -3 and placebo, respectively (p ns). Comorbid conditions were registered in 19 patients of the sample (36.5%): 13 (25%) patients with diabetes mellitus (DM2) and nine patients (17.3%) with systemic arterial hypertension (HAS). Twenty-seven patients (52%) were premenopausal. Four (7.7%) patients were classified as stage IIA, 20 (38.5%) patients as IIB, 22 (42.3%) patients as IIIA and six (11.5%) patients as IIIB. Infiltrating ductal carcinoma was the most prevalent histological subtype, presented in 46 (90%) patients. Clinical characteristics of the patients are shown in table I.

Adverse events

The most common data of toxicity secondary to the administration of chemotherapy were hematological alterations: leukopenia, neutropenia and anemia were similar in both groups and there was no significant difference between them. As a consequence of hematological toxicity, seven patients (27%) of the PUFA Ω -3 and nine patients (35%) of the placebo group had a delay in the administration of treatment with adriamycin-cyclophosphamide and, during the administration of treatment with paclitaxel, five (20%) patients from the PUFA Ω -3 group and seven (28%) patients from the placebo group postponed their administration.

No significant differences in symptoms related to gastrointestinal toxicity such as nausea, vomiting, diarrhea and mucositis were found between groups, neither in fatigue nor neuropathy. These results are shown in table II.

Edmonton scale assessment

Both the PUFA Ω -3 and placebo groups presented a similar significant increase at three and six months in the fatigue scales ($p = 0.001$), nausea ($p = 0.031$), drowsiness ($p = 0.001$), appetite ($p = 0.002$) and dyspnea ($p = 0.033$); however, no significant differences were found between groups. Pain, discouragement and anxiety did not present statistically significant changes during the time (three and six months of the intervention). Xerostomia scale showed a significant decrease in the intensity of this symptom over time (three and six months) in the group supplemented with PUFA Ω -3 ($p = 0.0001$). This symptom also showed a significant decrease in the group supplemented with PUFA Ω -3 ($p = 0.032$), compared with the placebo one.

Body weight and composition

At the beginning of the study, 77.7% of the patients were overweight. Body weight and BMI showed no statistically significant difference during the time the study was carried out or between the groups. Average weight loss for the group supplemented with PUFA Ω -3 was 1.8 kg, while the group that received the placebo presented a weight increase of 0.5 kg (Table III).

The skeletal muscle index (SMI) showed a significant ($p = 0.02$) increase over time in both groups but no difference was found when compared between groups. Fat free mass (FFM) exhibited the same phenomenon. For its side, body fat showed a significant reduction during the time of measurements at three and six months in the group supplemented with

PUFA Ω -3 ($p = 0.02$), while in the patients receiving placebo it did not present changes. These results are shown in table III.

Cardiometabolic profile

Carbohydrate metabolism (serum glucose, insulin, HOMA-IR, HbA1c) was not affected by NeoCT over time in any group. In the lipid profile, a significant increase in the concentration of triglycerides (TG) at three and six months ($p = 0.0001$) was found in both groups. Similarly, cholesterolemia was significantly higher at three and six months ($p = 0.04$), but no differences were found when comparing the effect of the supplementation with PUFA Ω -3 vs placebo. On the opposite, HDL presented a significant reduction in both groups ($p = 0.0001$); this effect was not significant when it was compared between the two groups.

Serum albumin showed a reduction that was statistically significant ($p = 0.0001$), however, this effect was not significant in relation to PUFA Ω -3 or placebo groups. Also, alanine aminotransferase (ALT) was measured to evaluate liver damage. The two groups show an increase considered to be still normal, which was significant at three and six months ($p = 0.002$). Protein degradation was assessed by the concentration of urea nitrogen (BUN). The changes were not significant over time in any group.

DISCUSSION

In the present study, the effects of oral supplementation with PUFA Ω -3 (DHA and EPA) on the toxic effects of NeoCT in patients with LABC were investigated.

Previous studies evaluated treatment efficacy and indirect toxicity with the quality of life scales and with the CTCAE (version 4.03). The present study is the first to consider the perception of some symptoms associated with the toxicity of the patient with the Edmonton scale (18). In general, no statistically significant effects were observed in toxicity; however, the patients who received the supplement with PUFA Ω -3

presented improvement in the scale of xerostomia. This result could support the one reported by a previous study, where it was found that supplementation with PUFA Ω -3 in patients with esophageal cancer and treated with NeoCT decreases mucosal damage induced by chemotherapy (14). The protective effect of PUFA Ω -3 was related to the reduction of systemic inflammation, since PUFA Ω -3 modulates the production of proinflammatory cytokines and the production of anti-inflammatory eicosanoids and, indirectly, promotes the decrease in the production of TNF-alpha and IL-6 (23,24).

Although PUFA Ω -3 is rapidly incorporated into blood cells during consumption, no improvement in hematological toxicity was observed (14). The results of this study indicate that supplementation with PUFA Ω -3 does not protect against the hematological toxicity induced by chemotherapy. There are studies reporting that a combined chemotherapy treatment (as the one used in the present study) is more severe as compared to a monotherapy and the hematological toxicity (neutropenia and leukopenia) is substantially higher in treatments with polychemotherapy (6). The results of the present study show no positive effect with PUFA Ω -3 supplementation, and this may be due to the therapy that was used, namely, adriamicin-cyclophosphamide and paclitaxel +/- trastuzumab (polychemotherapy, 12 weeks), whose side effects were surely more severe. Interestingly, and contrary to this result, the group of Miyata et al. (2012) showed that PUFA Ω -3 in NeoCT have positive effects on hematological toxicity in a cohort of patients with esophageal cancer treated with monotherapy (paclitaxel) (25).

From the clinical and epidemiological point of view, body composition plays an important role to prevent or treat different diseases. In a meta-analysis where the effect of supplementation with PUFA Ω -3 during chemotherapy on body composition was evaluated, Buckinx et al. (2015) (26) reported that the most common benefit is to increase or preserve body weight (6). The results of this study show that most of the patients

had a decrease in muscle mass and a high percentage of body fat (sarcopenic obesity) before starting NeoCT. However, during the administration of chemotherapy, both groups showed an increase that was significant in the fat-free mass and the skeletal muscle index. In addition, the patients of the group supplemented with PUFA Ω -3 also had a greater reduction of mass body fat, while the placebo group showed a slight increase. There were no new cases of sarcopenic obesity during the whole treatment with chemotherapy. The results observed differ from those reported by other authors in different studies of breast cancer in advanced stages, as they report a greater amount of patients with obesity and sarcopenia during treatment (10,27). It is possible that the difference in the results is associated with the clinical stage of the disease.

In line with this, Ayca et al. (2018) reported that supplementation with DHA during chemotherapy using only one drug did not cause significant changes in inflammatory mediators or body composition of overweight and obese patients. They reported that, probably, no significant changes in body composition were found due to the differences between the study population, the dose and the duration of supplementation with DHA (3). In addition, Hames (2017) reported that, after administration of PUFA Ω -3 for six months at high doses, it increased significantly in plasma and adipose tissue. However, the changes did not show beneficial effects on markers of inflammation and in the number or subtype of macrophages present in the adipose tissue. In this study, they reported that possibly no positive effects were found due to the presence of obesity, overweight and the insulin resistance present in the patients (28). In the same way, Kratz et al. (2013) showed that supplementation with PUFA Ω -3 for 14 weeks in overweight and obese people had no effect on the expression of genes, which regulate the production of inflammatory mediators, including TNF- α in the adipose tissue (29). According to the results of these studies, it should be

considered that one of the possible causes for which no statistically significant changes were found, in body composition and chemotoxicity, is the type of patients included in the present study, who were also overweight, obese and with sarcopenia before starting NeoCT.

Some studies have shown that PUFA Ω -3 reduce triglycerides. This effect has been related mainly to the decrease in the production of very low-density lipoproteins (VLDL) and, secondly, to the increase in HDL (30). However, the results of this research work show an opposite effect, since there was a significant increase in triglycerides and a reduction in HDL cholesterol in the two groups of patients. These results support what Sharma et al., who investigated changes in lipid metabolism during chemotherapy in patients with breast cancer in stage IA, IIA, IIB and IIIC, reported in their study (2016). Their results showed that the administration of doxorubicin decreases HDL and the administration of paclitaxel causes a significant increase in VLDL and triglycerides.

On the other hand, some studies suggest that the administration of PUFA Ω -3 increases insulin sensitivity, predominantly by reducing body fat mass (31-33). In the present study, the group of patients supplemented with PUFA Ω -3 presented a significant reduction in body fat mass; however, this change did not increase sensitivity to insulin. These findings support what has been reported by other studies, where association between supplementation with PUFA Ω -3 and insulin sensitivity was not demonstrated (28,33). It appears that the effects of PUFA Ω -3 may vary according to the severity of the disease and some characteristics of patients, such as excessive weight and insulin resistance (34).

Finally, we must mention that the lack of effect of PUFA Ω -3 in the studied patients could also be the result of other factors such as dose, type of cancer, administration scheme or even the number of patients studied. Although these parameters were used according to other similar studies reported in lung cancer, esophageal cancer, metastatic breast

cancer and women at high risk of breast cancer, these may not be adequate for the pathology and the type of patients studied in the present work (13,15,35,36).

The results of this study do not support the hypothesis that PUFAs Ω -3 improve the adverse effects of NeoCT in women with LABC.

CONCLUSIONS

The results of this study indicate that supplementation with PUFA Ω -3 during neoadjuvant therapy in patients with LABC only reduces the symptoms of xerostomia. No significant differences were found in body composition, so we concluded that supplementation does not contribute to preserve weight and body composition during treatment with NeoCT. Hematological toxicity also did not show significant changes induced by PUFA Ω -3. However, it is important to consider that these results do not exclude the protective role of PUFA Ω -3 and its use as coadjuvant therapy in patients with other types of cancer. Future studies should focus on confirming these results and design suitable clinical trials to determine the proper dose and duration of PUFA Ω -3 supplementation. In addition, inflammatory markers should be assessed to evaluate the anti-inflammatory benefit of the administration of PUFA Ω -3 during the treatment of NeoCT.

Study limitations

The patients included are subjected to a rigorous scrutiny that qualifies them to receive or not care in the hospital, so from the beginning, they are patients already screened, for a better profile selection, and this could bias the results, not showing the potential benefit in a “common and current” patient.

ACKNOWLEDGMENTS

The authors acknowledge all of the investigators, coordinators and patients who took part in this study.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136(5):E359-86.
2. Gerber B, Scholz C, Reimer T, Briese V, Janni W. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. *Breast Cancer Res Treat* 2006;95(3):199-209.
3. Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, et al. A randomized multicenter phase II study of docosahexaenoic acid in patients with a history of breast cancer, premalignant lesions or benign breast disease. *Cancer Prev Res* 2018;11(4):203-214.
4. Murphy RA, Mourtzakis M, Mazurak VC. n-3 polyunsaturated fatty acids: the potential role for supplementation in cancer. *Curr Opin Clin Nutr Metab Care* 2012;15(3):246-51.
5. Buoite Stella A, Gortan Cappellari G, Barazzoni R, Zanetti M. Update on the impact of omega 3 fatty acids on inflammation, insulin resistance and sarcopenia: a review. *Int J Mol Sci* 2018;19(1):218.
6. Silva JdAP, De Souza Fabre ME, Waitzberg DL. Omega-3 supplements for patients in chemotherapy and/or radiotherapy: a systematic review. *Clin Nutr* 2015;34(3):359-66.
7. Vaughan V, Hassing M, Lewandowski P. Marine polyunsaturated fatty acids and cancer therapy. *Br J Cancer* 2013;108(3):486.
8. Palmela C, Velho S, Agostinho L, Branco F, Santos M, Santos MPC, et al. Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer. *J Gastric Cancer* 2017;17(1):74-87.

9. Mourtzakis M, Bedbrook M. Muscle atrophy in cancer: a role for nutrition and exercise. *Appl Physiol Nutr Metab* 2009;34(5):950-6.
10. Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. *J Clin Oncol* 2001;19(9):2381-9.
11. McDonald C, Bauer J, Capra S, Coll J. The muscle mass, omega-3, diet, exercise and lifestyle (MODEL) study—a randomised controlled trial for women who have completed breast cancer treatment. *BMC Cancer* 2014;14(1):264.
12. Alfano CM, Imayama I, Neuhaus ML, Kiecolt-Glaser JK, Smith AW, Meeske K, et al. Fatigue, inflammation, and Ω -3 and Ω -6 fatty acid intake among breast cancer survivors. *J Clin Oncol* 2012;30(12):1280.
13. Bougnoux P, Hajjaji N, Ferrasson M, Giraudeau B, Couet C, Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. *Br J Cancer* 2009;101(12):1978-85.
14. Miyata H, Yano M, Yasuda T, Yamasaki M, Murakami K, Makino T, et al. Randomized study of the clinical effects of Ω -3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. *Nutrition* 2017;33:204-10.
15. Murphy R, Yeung E, Mazurak V, Mourtzakis M. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. *Br J Cancer* 2011;105(10):1469-73.
16. Hassett MJ, O'malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. *J Natl Cancer Inst* 2006;98(16):1108-17.

17. Donker M, Straver ME, Rutgers EJ, Valdes Olmos RA, Loo CE, Sonke GS, et al. Radioguided occult lesion localisation (ROLL) in breast-conserving surgery after neoadjuvant chemotherapy. *Eur J Surg Oncol* 2012;38(12):1218-24.
18. Carvajal A, Centeno C, Watson R, Bruera E. A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients. *Eur J Cancer* 2011;47(12):1863-72.
19. Bini R, Comelli S, Leli R, Vaudano GP, Savio D, Viora T, et al. A novel approach to inoperable or recurrent rectal cancer by chemoembolization. A new arrow in our quiver? *Oncotarget* 2016;7(29):45275.
20. Ling CH, De Craen AJ, Slagboom PE, Gunn DA, Stokkel MP, Westendorp RG, et al. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population. *Clin Nutr* 2011;30(5):610-5.
21. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. *Endocr J* 2001;48(1):81-6.
22. Carrillo JF, Ortiz-Toledo MÁ, Salido-Noriega Z, Romero-Ventura NB, Ochoa-Carrillo FJ, Oñate-Ocaña LF. Validation of the Mexican Spanish version of the EORTC QLQ-H&N35 instrument to measure health-related quality of life in patients with head and neck cancers. *Ann Surg Oncol* 2013;20(5):1417-26.
23. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? *Br J Clin Pharmacol* 2013;75(3):645-62.
24. Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. *Mol Nutr Food Res* 2008;52(8):885-97.

25. Miyata H, Yano M, Yasuda T, Hamano R, Yamasaki M, Hou E, et al. Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. *Clin Nutr* 2012;31(3):330-6.
26. Buckinx F, Reginster JY, Dardenne N, Croisier JL, Kaux JF, Beudart C, et al. Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a cross-sectional study. *BMC Musculoskelet Disord* 2015;16:60.
27. Carneiro IP, Mazurak VC, Prado CM. Clinical implications of sarcopenic obesity in cancer. *Curr Oncol Rep* 2016;18(10):62.
28. Hames KC, Morgan-Bathke M, Harteneck DA, Zhou L, Port JD, Lanza IR, et al. Very-long-chain Ω -3 fatty acid supplements and adipose tissue functions: a randomized controlled trial. *Am J Clin Nutr* 2017;105(6):1552-8.
29. Kratz M, Kuzma JN, Hagman DK, Van Yserloo B, Matthys CC, Callahan HS, et al. n3 PUFAs do not affect adipose tissue inflammation in overweight to moderately obese men and women. *J Nutr* 2013;143(8):1340-7.
30. Shearer GC, Savinova OV, Harris WS. Fish oil: how does it reduce plasma triglycerides? *Biochim Biophys Acta* 2012;1821(5):843-51.
31. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. *Adv Nutr* 2011;2(4):304-16.
32. Han CY, Kargi AY, Omer M, Chan CK, Wabitsch M, O'Brien KD, et al. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. *Diabetes* 2010;59(2):386-96.
33. Bhaswant M, Poudyal H, Brown L. Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids. *J Nutr Biochem* 2015;26(6):571-84.

34. Spencer M, Finlin BS, Unal R, Zhu B, Morris AJ, Shipp LR, et al. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. *Diabetes* 2013;62(5):1709-17.
35. Ryan AM, Reynolds JV, Healy L, Byrne M, Moore J, Brannelly N, et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. *Ann Surg* 2009;249(3):355-63.
36. Yee LD, Lester JL, Cole RM, Richardson JR, Hsu JC, Li Y, et al. Ω -3 Fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. *Am J Clin Nutr* 2010;91(5):1185-94.

Nutrición
Hospitalaria

Table I. Enrolment and baseline characteristics of studied subjects

| <i>Enrolment characteristics, n (%)</i> | <i>PUFA Ω-3 (n = 26)</i> | <i>Placebo (n = 26)</i> | <i>p-value</i> |
|---|--|-----------------------------|----------------|
| <i>mean \pm (ESM)</i> | | | |
| Age (y) | 50.7 \pm 2.1 | 49.5 \pm 2.1 | 0.64 |
| Premenopausal | 13 (50) | 15 (57.7) | 0.22 |
| Postmenopausal | 13 (50) | 11 (42.3) | |
| Comorbidities: | | | |
| DM2 | 7 (26.9) | 6 (23) | 0.79 |
| HAS | 6 (23) | 3 (11.5) | |
| Stage | | | |
| IIA | 1 (3.8) | 3 (11.5) | 0.58 |
| IIB | 9 (34.6) | 11 (42.3) | |
| IIIA | 13 (50) | 9 (34.6) | |
| IIIB | 3 (11.5) | 3 (11.5) | |
| Histologic subtype | | | |
| Ductal | 22 (84.6) | 24 (92.3) | 0.65 |
| Lobulillar | 3 (11.5) | 2 (7.7) | |
| Molecular subtype | | | |
| Luminal A | 7 (26.9) | 7 (26.9) | 0.94 |
| Luminal B | 15 (57.7) | 14 (53.8) | |
| Triple negative | 3 (11.5) | 3 (11.5) | 0.94 |
| Her positive | 11 (42.3) | 12 (46.1) | 0.78 |
| Baseline characteristics | | | |
| Blood pressure (mmHg) | | | |
| Systolic | 120 \pm 3.3 | 119 \pm 3.7 | 0.69 |
| Diastolic | 75.7 \pm 1.9 | 74.1 (1.6) | 0.54 |
| Glucose (mg/dl) | 108.5 \pm 8 | 104.5 \pm 6.8 | 0.70 |
| Insulin (μ U/dl) | 13.8 \pm 3.2 | 11.5 \pm 2.3 | 0.58 |
| HOMA-IR | 4.3 \pm 1.3 | 3.1 \pm 0.8 | 0.47 |
| Triglycerides (mg/dl) | 149 \pm 11 | 137 \pm 14.2 | 0.48 |
| Cholesterol (mg/dl) | 183 \pm 7.1 | 187.2 \pm 6.3 | 0.66 |
| HbA1c (%) | 6.3 \pm 0.3 | 6 \pm 0.3 | 0.50 |
| Height (m) | 1.55 \pm 1.01 | 1.54 \pm 1.01 | 0.66 |
| Weight (kg) | 68 \pm 1.8 | 67.4 \pm 2 | 0.79 |
| Body mass index (kg/m ²) | 28.6 \pm 0.8 | 29.1(1.1) | 0.24 |
| Body fat mass (%) | 41.5 \pm 1 | 41.2 \pm 1.2 | 0.85 |
| Abdominal perimeter (cm) | 92.9 (1.5) | 92.6 (2.3) | 0.93 |

Data reported as mean \pm standard error (SEM). PUFA Ω -3: omega-3 polyunsaturated fatty acids.

Table II. Toxicity in neoadjuvant treatment during the addition of PUFA Ω -3 or placebo

| Adverse events | PUFA Ω -3 (n = 26) | | Placebo (n = 26) | | p value |
|----------------|---------------------------|-------------------------|------------------|-------------------------|---------|
| | Grade 0 n (%) | Grade \geq 1 n (%) | Grade 0 n (%) | Grade \geq 1 n (%) | |
| Leukopenia | | | | | |
| 3 months | 20 (76.9) | 6 (23.1) | 22 (84.6) | 4 (15.4) | 0.72 |
| 6 months | 17 (65.4) | 9 (34.6) | 12 (46.9) | 14 (53.8) | 0.26 |
| Neutropenia | | | | | |
| 3 months | 18 (69.2) | 8 (30.8) | 19 (73.1) | 7 (26.9) | 0.11 |
| 6 months | 15 (57.7) | 11 (42.3) | 13 (50) | 13 (50) | 0.78 |
| Anemia | | | | | |
| 3 months | 18 (69.2) | 8 (30.8) | 19 (73.1) | 7 (26.9) | 1.00 |
| 6 months | 12 (46.2) | 14 (53.8) | 16 (61.5) | 10 (38.5) | 0.40 |
| Nausea | | | | | |
| 3 months | 22 (84.6) | 4 (15.4) | 23 (88.5) | 3 (11.5) | 1.00 |
| 6 months | 24 (92.3) | 2 (7.7) | 23 (28.5) | 3 (11.5) | 1.00 |
| Vomiting | | | | | |
| 3 months | 22 (84.6) | 4 (15.4) | 23 (88.5) | 3 (11.5) | 1.00 |
| 6 months | 25 (96.2) | 1 (3.8) | 24 (92.3) | 2 (7.7) | 1.00 |
| Diarrhea | | | | | |
| 3 months | 22 (84.6) | 4 (15.4) | 23 (88.5) | 3 (11.5) | 1.00 |
| 6 months | 25 (96.2) | 1 (3.8) | 21 (80.8) | 5 (19.2) | 0.19 |

| | | | | | | |
|------------|---|-----------|-----------|-----------|-----------|------|
| Neuropathy | | | | | | |
| 3 months | 3 | 23 (88.5) | 3 (11.5) | 24 (92.3) | 2 (7.7) | 0.66 |
| 6 months | 6 | 14 (53.8) | 12 (46.2) | 12 (46.1) | 14 (53.8) | 0.50 |
| Fatigue | | | | | | |
| 3 months | 3 | 16 (61.5) | 10 (38.5) | 14 (53.8) | 12 (46.2) | 0.50 |
| 6 months | 6 | 20 (76.9) | 6 (23.1) | 18 (69.2) | 8 (30.8) | 0.75 |
| Mucositis | | | | | | |
| 3 months | | 24 (92.3) | 2 (7.7) | 23 (88.5) | 3 (11.5) | 1.00 |
| 6 months | | 25 (96.2) | 1 (3.8) | 26 (100) | 0 (0) | 1.00 |

Reported data of Fisher's exact test. PUFA Ω -3: omega 3 polyunsaturated fatty acids; ns: non-significant. The evaluation of adverse events was performed according to CTCAE (version 4.03, June 2010).

Table III. Body composition

| Body parameters | | | | |
|-----------------------------|-------------------------|------------------------|----------------------|--|
| Treatment group | Basal | 3 months | 6 months | |
| Weight (kg) | | | | |
| PUFA Ω -3 | 68 \pm 1.8 (64-71) | 66.6 \pm 1.8 (62.7- | 66.2 \pm 1.7 | |
| Placebo | 67.4 \pm 2 (63.1- | 70.4) | (62.7-69.8) | |
| | 71.7) | 67.5 \pm 2 (63.3- | 67.9 \pm 2 (63.4- | |
| | | 71.7) | 72.4) | |
| Body mass index | | | | |
| (kg/m ²) | 28.2 \pm 0.8 (26.4- | 27.6 \pm 0.8 (25.9- | 27.4 \pm 1 (25.8- | |
| PUFA Ω -3 | 29.9) | 29.3) | 29) | |
| Placebo | 28.4 \pm 1 (26.3- | 28.4 \pm 0.3 (26.4- | 28.6 \pm 1 (26.5- | |
| | 30.5) | 30.4) | 31) | |
| Skeletal muscle mass | | | | |
| index (kg/m ²) | | | | |
| PUFA Ω -3 | 5.83 \pm 0.12 (5.5-6) | 6 \pm 0.12 (5.7-6.2) | 6.0 \pm 0.14 (5.7- | |
| Placebo | 5.9 \pm 0.15 (5.5- | 5.8 \pm 0.11 (5.2- | 6.3) | |
| | 6.2) | 6.3) | 6.1 \pm 0.15 (5.8- | |
| | | | 6.4) | |
| Fat-free mass (kg) | | | | |
| PUFA Ω -3 | 37.3 \pm 0.8 (35.6- | 39.4 \pm 0.8 (37.7- | 39.2 \pm 0.8 | |
| Placebo | 39) | 41) | (37.4-41) | |
| | 37 \pm 0.9 (35.1- | 39.2 \pm 0.9 (37.3- | 39.8 \pm 1 (37.7- | |
| | 38.9) | 41.2) | 41.8) | |
| Fat mass MG (kg) | | | | |
| PUFA Ω -3 | 28.5 \pm 1.3 (25.8- | 28.0 \pm 1.2 (25.4- | 27 \pm 1.2 (24.4- | |
| Placebo | 31.2) | 30.6) | 29.5) | |
| | 28.3 \pm 1.5 (25- | 28.1 \pm 1.3 (25- | 28.4 \pm 1.4 | |
| | 31.5) | 31.5) | (25.5-31.3) | |
| Percent body fat (%) | | | | |

| | | | |
|------------------|-----------------------|-----------------------|----------------|
| PUFA Ω -3 | 41.5 \pm 1 (39.3- | 41.7 \pm 0.9 (39.7- | 40.6 \pm 0.9 |
| Placebo | 43.6) | 43.7) | (38.642.7) |
| | 40.7 \pm 1.2 (38.1- | 41.2 \pm 0.9 (39.1- | 40.7 \pm 0.9 |
| | 43.4) | 43.2) | (38.842.7) |

Data reported as mean \pm standard error (ESM). PUFA Ω -3: omega 3 polyunsaturated fatty acids; CI: 95% confidence interval. Analyzed by the ANOVA test of repeated measures. Statistically significant difference at $p < 0.05$).






Fig. 1. CONSORT. The algorithm of allocation of study subjects to analyzed groups. Fifty-three women diagnosed with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy and randomized to receive a capsule supplement with omega 3 polyunsaturated fatty acids (PUFA Ω -3) or placebo. Only one patient discontinued the treatment (omega 3 supplementation) because of lack of interest in supplementation.